NRIX

+ Watchlist + Portfolio

Nurix Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $23.34
52-Week Range: $9.00 – $28.23
Market Cap: $2.39B
P/E (TTM): —
EPS (TTM): -3.46
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 5.92
PEG Ratio: —
Return on Equity: -80.30%
Return on Assets: -40.06%
Gross Margin: 0.00%
Operating Margin: -1041.73%
Profit Margin: 0.00%
Current Ratio: 6.34
Debt/Equity: 0.14
Total Debt: $58.14M
Free Cash Flow: $-164.64M
Revenue Growth: -79.50%
Earnings Growth: —
Enterprise Value: $2.00B

NRIX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$38.63M	$76.99M	$54.55M	$83.98M
Research & Development	$184.50M	$189.15M	$221.63M	$316.90M
Selling, General & Admin	$38.00M	$42.90M	$45.94M	$52.74M
Operating Expenses	$222.49M	$232.05M	$267.58M	$369.65M
Operating Income	-$183.87M	-$155.06M	-$213.03M	-$285.67M
EBITDA	-$173.06M	-$141.41M	-$196.60M	-$266.81M
Pretax Income	-$180.36M	-$143.95M	-$193.30M	-$263.70M
Income Tax	$0.00	$0.00	$270.00K	$760.00K
Net Income	-$180.36M	-$143.95M	-$193.57M	-$264.46M
Diluted EPS	-3.71	-2.65	-2.88	-3.05
Diluted Shares	48.61M	54.34M	67.12M	86.67M

NRIX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$64.47M	$54.63M	$110.00M	$246.96M
Receivables	$0.00	—	—	—
Current Assets	$318.45M	$295.50M	$619.39M	$606.82M
Total Assets	$416.76M	$355.60M	$669.34M	$688.13M
Current Liabilities	$70.66M	$86.96M	$95.85M	$86.47M
Total Debt	$11.96M	$30.61M	$28.30M	$55.73M
Total Liabilities	$113.06M	$155.10M	$142.35M	$149.39M
Retained Earnings	-$401.25M	-$545.20M	-$738.77M	-$1.00B
Shareholders' Equity	$303.70M	$200.49M	$526.99M	$538.75M
Working Capital	$247.79M	$208.54M	$523.53M	$520.35M

NRIX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$159.81M	-$81.36M	-$172.58M	-$249.47M
Capital Expenditure	-$12.24M	-$8.40M	-$9.27M	-$14.00M
Free Cash Flow	-$172.05M	-$89.77M	-$181.86M	-$263.47M
Depreciation & Amortisation	$10.81M	$13.65M	$16.43M	$18.86M
Stock-Based Compensation	$28.13M	$33.67M	$33.93M	$37.97M
Investing Cash Flow	$27.20M	$68.30M	-$257.71M	$147.85M
Financing Cash Flow	$117.19M	$3.22M	$485.67M	$238.64M
Net Change in Cash	-$15.42M	-$9.85M	$55.37M	$137.03M

NRIX Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$44.06M	$7.89M	$13.58M	$6.25M	$9.04M
Research & Development	$78.10M	$86.12M	$83.02M	$84.14M	$87.65M
Selling, General & Admin	$14.28M	$13.16M	$13.65M	$14.61M	$15.59M
Operating Expenses	$92.38M	$99.28M	$96.67M	$98.75M	$103.25M
Operating Income	-$48.32M	-$91.39M	-$83.09M	-$92.50M	-$94.20M
EBITDA	-$43.23M	-$86.39M	-$78.46M	-$88.72M	-$90.35M
Pretax Income	-$42.70M	-$86.42M	-$78.22M	-$87.17M	-$89.81M
Income Tax	$760.00K	$0.00	$0.00	—	-$271.00K
Net Income	-$43.46M	-$86.42M	-$78.22M	-$87.17M	-$89.53M
Diluted EPS	-0.52	-1.03	-0.82	-0.79	-0.81
Diluted Shares	83.88M	84.16M	95.09M	110.07M	111.08M

NRIX Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$84.26M	$78.44M	$246.96M	$71.19M	$67.69M
Receivables	$19.00M	—	—	—	—
Current Assets	$515.33M	$440.60M	$606.82M	$554.39M	$456.48M
Total Assets	$591.55M	$522.47M	$688.13M	$636.13M	$535.54M
Current Liabilities	$75.61M	$82.35M	$86.47M	$92.20M	$72.02M
Total Debt	$51.93M	$56.49M	$55.73M	$58.66M	$58.14M
Total Liabilities	$143.95M	$150.22M	$149.39M	$155.24M	$132.91M
Retained Earnings	-$838.58M	-$925.00M	-$1.00B	-$1.09B	-$1.18B
Shareholders' Equity	$447.60M	$372.25M	$538.75M	$480.89M	$402.63M
Working Capital	$439.72M	$358.25M	$520.35M	$462.19M	$384.46M

NRIX Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$63.16M	-$57.38M	-$67.83M	-$71.91M	-$96.57M
Capital Expenditure	-$2.67M	-$2.71M	-$5.13M	-$1.04M	-$1.94M
Free Cash Flow	-$65.84M	-$60.10M	-$72.96M	-$72.96M	-$98.51M
Depreciation & Amortisation	$5.10M	$5.00M	$4.63M	$3.78M	$3.85M
Stock-Based Compensation	$10.38M	$9.77M	$9.09M	$9.40M	$11.39M
Investing Cash Flow	$71.50M	$50.48M	$346.00K	-$123.83M	$93.00M
Financing Cash Flow	$6.00K	$1.16M	$236.01M	$19.98M	$66.00K
Net Change in Cash	$8.34M	-$5.75M	$168.52M	-$175.76M	-$3.51M

Market Snapshot

About

Nurix Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted protein degradation therapies for cancer and immune disorders. The company uses its proprietary DELigase platform to discover small molecules that harness the ubiquitin-proteasome system to degrade disease-causing proteins. Nurix has multiple drug candidates in clinical development targeting difficult-to-treat cancers and inflammatory diseases.